Photo of Vinay Prasad, MD, MPH

Vinay Prasad MD, MPH

Dr. Prasad specializes in caring for patients with hematologic malignancies, including Non-Hodgkin’s and Hodgkin’s lymphoma, chronic lymphocytic leukemia/lymphoma, mantle cell lymphoma and follicular lymphoma among others. He has advanced training in hematology (diseases of the blood and bone marrow) and oncology (cancer).  At OHSU, he is part of the lymphoma team, where he specializes in the care of people with hematologic malignancies, using chemotherapy, biological therapies, targeted therapies and immunotherapy to improve their health.

Dr. Prasad is nationally known for his research that seeks to improve the medical decisions doctors make, and improve the quality of evidence that doctors use to treat patients. He enjoys working with patients and their families to develop personalized treatment plans, and guide them through their care.  Dr. Prasad is the author of Ending Medical Reversal: Improving Outcomes, Saving Lives.

In his spare time, Dr. Prasad is an avid cyclist. He enjoys basketball, tennis, reading, gardening and occasionally binge-watching television.

Read more

Education

  • M.D., University of Chicago 2009
  • M.P.H., Johns Hopkins University 2014
  • Residency:

    • Internal Medicine, Northwestern University, 2012
  • Fellowship:

    • Oncology, National Cancer Institute; Hematology, National Heart Lung Blood Institute, 2015
  • Certifications:

    • American Board of Internal Medicine (Internal Medicine) 2012; Medical Oncology and Hematology (2015)

Memberships and associations

  • American Society of Clinical Oncology

Publications

  • "Brentuximab vedotin for frontline Hodgkin lymphoma : How much will a successful trial cost patients and payers?" European Journal of Cancer  In: , Vol. 104, 01.11.2018, p. 252-253.
  • "Inconsistent Reporting of Potential Conflicts of Interest." JAMA Oncology  In: , Vol. 4, No. 10, 01.10.2018.
  • "Inconsistent Reporting of Potential Conflicts of Interest." JAMA Internal Medicine  In: , Vol. 178, No. 10, 01.10.2018, p. 1424-1425.
  • "A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature." European Journal of Cancer  In: , Vol. 101, 01.09.2018, p. 143-151.
  • "A pooled analysis of published, basket trials in cancer medicine." European Journal of Cancer  In: , Vol. 101, 01.09.2018, p. 244-250.
  • "Why is research in early-stage cancer research so low?" Journal of Cancer Policy  In: , Vol. 17, 01.09.2018, p. 4-8.
  • "In reply." JAMA Oncology  In: , Vol. 4, No. 9, 01.09.2018, p. 1300-1301.
  • "Inconsistent Reporting of Potential Conflicts of Interest." JAMA Pediatrics  In: , Vol. 172, No. 9, 01.09.2018.
  • "Improving observational studies in the era of big data." The Lancet  In: , Vol. 392, No. 10149, 01.09.2018, p. 716-717.
  • "Choice of control group in randomised trials of cancer medicine : are we testing trivialities?" The Lancet Oncology  In: , Vol. 19, No. 9, 01.09.2018, p. 1150-1152.
  • "Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology." JAMA Oncology  In: , Vol. 4, No. 8, 01.08.2018, p. 1093-1098.
  • "Inconsistent reporting of potential conflicts of interest." JAMA - Journal of the American Medical Association  In: , Vol. 320, No. 4, 24.07.2018.
  • "Cost-effectiveness of nusinersen for spinal muscular atrophy : Reply." JAMA Pediatrics  In: , Vol. 172, No. 7, 01.07.2018, p. 701-702.
  • "Total costs of chimeric antigen receptor T-cell immunotherapy." JAMA oncology  In: , Vol. 4, No. 7, 01.07.2018, p. 994-996.
  • "Direct-to-consumer genetic testing the implications of the US FDA's first marketing authorization for BRCA mutation testing." JAMA - Journal of the American Medical Association  In: , Vol. 319, No. 23, 19.06.2018, p. 2377-2378.
  • "If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis." Journal of General Internal Medicine  In: , 04.06.2018, p. 1-2.
  • "The US Food and Drug Administration's use of pathologic complete response as regulatory endpoint : Did it pay off?" Journal of Cancer Policy  In: , Vol. 16, 01.06.2018, p. 49-51.
  • "Concerns about the approval of nusinersen sodium by the US food and drug administration." JAMA Internal Medicine  In: , Vol. 178, No. 6, 01.06.2018, p. 743-744.
  • "Low-value approvals and high prices might incentivize ineffective drug development." Nature Reviews Clinical Oncology  In: , 14.05.2018, p. 1-2.
  • "When is crossover desirable in cancer drug trials and when is it problematic?" Annals of Oncology  In: , Vol. 29, No. 5, 01.05.2018.
  • "In reply." JAMA Internal Medicine  In: , Vol. 178, No. 4, 01.04.2018, p. 588-589.
  • "In reply." JAMA oncology  In: , Vol. 4, No. 4, 01.04.2018, p. 586-587.
  • "Crossover is not associated with faster trial accrual." Annals of Oncology  In: , Vol. 29, No. 3, mdx821, 01.03.2018, p. 776-777.
  • "Without randomized studies, the costeffectiveness of a therapy cannot be known." Annals of Oncology  In: , Vol. 29, No. 3, 01.03.2018, p. 527-529.
  • "PFO closure for secondary stroke prevention : is the discussion closed?" Journal of Thrombosis and Thrombolysis  In: , 20.02.2018, p. 1-3.
  • "Nusinersen for spinal muscular atrophy are we paying too much for too little?" JAMA Pediatrics  In: , Vol. 172, No. 2, 01.02.2018, p. 123-125.
  • "Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it." Annals of Oncology  In: , Vol. 29, No. 2, 01.02.2018, p. 298-300.
  • "Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers." JAMA oncology  In: , Vol. 4, No. 2, 01.02.2018, p. 157-158.
  • "Tisagenlecleucel - The first approved CAR-T-cell therapy : Implications for payers and policy makers." Nature Reviews Clinical Oncology  In: , Vol. 15, No. 1, 01.01.2018, p. 11-12.
  • "Pemetrexed in nonsquamous non-small-cell lung cancer : The billion dollar subgroup analysis." JAMA oncology  In: , Vol. 4, No. 1, 01.01.2018, p. 17-18.

Additional information

Edit profile